Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Clinical Pharmacokinetics

Volumn 54, Issue 8, 2015, Pages 859-874

  Namour, Florence ^a   Diderichsen, Paul Matthias ^c   Cox, Eugène ^c   Vayssière, Béatrice ^a   Van der Aa, Annegret ^b   Tasset, Chantal ^b   Van‘t Klooster, Gerben ^b  

^a Galapagos SASU   (France)

^b GALAPAGOS NV   (Belgium)

^c Certara Company   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FILGOTINIB; INTERLEUKIN 6; METHOTREXATE; PLACEBO; STAT1 PROTEIN; ANTIRHEUMATIC AGENT; JANUS KINASE 1; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ABSORPTION RATE CONSTANT; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG TREATMENT FAILURE; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; HUMAN; IC50; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 2 CLINICAL TRIAL; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHEUMATOID ARTHRITIS; SIMULATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHOSPHORYLATION;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEALTHY VOLUNTEERS; HUMANS; JANUS KINASE 1; MALE; MIDDLE AGED; PHOSPHORYLATION; PYRIDINES; TRIAZOLES;

EID: 84937967474     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0240-z     Document Type: Article

References (13)

1. O’Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36:542–50.
2. O’Shea JJ, Kontzias A, Yamaoko K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl. 2):111–5.
3. Ghoreschi K, Jesson M, Li X, Lee J, Ghosh S, Alsup J, Warner J, Tanaka M, Steward-Tharp S, Gadina M, Thomas C, Minnerly J, Storer C, LaBranche T, Radi Z, Dowty M, Head R, Meyer D, Kishore N, O’Shea J. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234–43.
4. Vaddi K, Luchi M. JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy. Expert Opin Investig Drug. 2012;21:961–73.
5. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24:513–26.
6. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93:397–409.
7. Haan C, Rolvering C, Raulf F, Kapp M, Druckes P, Thoma G, Behrmann I, Zerwes H. Jak1 has a dominant role over Jak3 in signal transduction through γc containing cytokine receptors. Chem Biol. 2011;18:314–23.
8. Van Rompaey L, Galien R, Van der Aar E, Clement-Lacroix P, Nelles L, Smets B, Lepescheux L, Christophe T, Conrath K, Vandeghinste N, Vayssiere B, De Vos S, Fletcher S, Brys R, Van ’t Klooster G, Feyen J, Menet C. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1 for the treatment of inflammatory diseases. J Immunol. 2013;191(7):3568–77.
9. Galien R, Vayssière B, De Vos S, Auberval M, Vandeghinste N, Dupont S, Clément-Lacroix P, Delerive P, Vanhoutte F, Brys R, Van der Aa A, Van Rompaey L, Van’t Klooster G. Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy subjects and rheumatoid arthritis patients. San Diego: American College of Rheumatology. Oct 2013 (Abstract no. 478).
10. Vanhoutte F, Mazur M, Van Der Aa A, Wigerinck P, Van’t Klooster G. Selective JAK1 inhibition in the treatment of rheulatoid arthritis: proof of concept with GLPG0634. Arthritis Rheum. 2012;64(Suppl. 10):2489.
11. U.S. Food and Drug Administration. Guidance for industry: population pharmacokinetics. Rockville: U.S. Food and Drug Administration; February 1999.
12. EMEA. Guideline on reporting the results of population pharmacokinetic analyses. London: EMEA; 2007 June.
13. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. 1989–2009 NONMEM users guides. Icon Development Solutions, Ellicott City (MD): USA.